Department of Dermatology, Northern Care Alliance NHS Foundation Trust, Manchester, UK.
Centre for Dermatology Research, The University of Manchester, Manchester, UK.
Clin Exp Dermatol. 2022 Aug;47(8):1536-1542. doi: 10.1111/ced.15226. Epub 2022 May 25.
Mohs micrographic surgery (MMS) for nonmelanoma skin cancer is often quoted as having an excellent safety profile.
To determine the complication rate of patients undergoing MMS in a large UK Mohs unit and subdivide complication rates into mild/intermediate and major, and to identify potential risk factors necessitating a clinical intervention.
This was a single-centre, cross-sectional study of 1000 consecutive cases of MMS performed with in-house repair. Notes from the postsurgical dressing clinics were reviewed at Visit 1 (Days 7-14) and Visit 2 (approximately Week 6). Based upon the intervention required and effect on cosmetic/functional outcome, complications were classified as minor, intermediate or major. Logistic regression modelling was used to identify risk factors associated with a complication that needed a clinical intervention (i.e. intermediate or major).
In total, 1000 Mohs surgeries were performed on 803 patients, resulting in 1067 excisions. Complication rates in our cohort were low (minor 3.6%, intermediate 3.1% and major 0.8%) Potential risk factors for developing a complication included skin graft (unadjusted OR = 4.89, 95% CI 1.93-12.39; fully adjusted OR = 7.13, 95% CI 2.26-22.45) and patients undergoing surgery on the forehead (unadjusted OR = 3.32, 95% CI 0.95-11.58; fully adjusted OR = 5.34, 95% CI 1.40-20.42). Patients whose wounds were allowed to heal by secondary intention healing (6.8%) exhibited no complications.
We advocate that patients should be informed during the consent procedure that less than 1 in every 100 patients (0.75%) undergoing MMS will have a serious adverse event (major complication) affecting their cosmetic or functional outcome.
Mohs 显微外科手术(MMS)治疗非黑色素瘤皮肤癌通常被认为具有极好的安全性。
确定在英国一家大型 Mohs 单位接受 MMS 治疗的患者的并发症发生率,并将并发症发生率细分为轻度/中度和重度,并确定需要临床干预的潜在危险因素。
这是一项在 1000 例连续 MMS 病例中进行的单中心、横断面研究,采用内部修复。在术后第 1 次就诊(第 7-14 天)和第 2 次就诊(大约第 6 周)时,对术后门诊就诊记录进行了回顾。根据需要的干预措施以及对美容/功能结果的影响,将并发症分为轻度、中度和重度。采用逻辑回归模型确定与需要临床干预(即中度或重度)的并发症相关的危险因素。
共对 803 例患者的 1000 次 Mohs 手术进行了分析,共进行了 1067 次切除。本队列的并发症发生率较低(轻度 3.6%,中度 3.1%,重度 0.8%)。潜在的危险因素包括皮肤移植(未调整的 OR=4.89,95%CI 1.93-12.39;完全调整的 OR=7.13,95%CI 2.26-22.45)和在前额接受手术的患者(未调整的 OR=3.32,95%CI 0.95-11.58;完全调整的 OR=5.34,95%CI 1.40-20.42)。让伤口自然愈合(6.8%)的患者没有出现并发症。
我们主张在手术知情同意过程中告知患者,不到每 100 例接受 MMS 治疗的患者中(0.75%)会发生影响其美容或功能结果的严重不良事件(重大并发症)。